NVAX - Novavax

-

$undefined

N/A

(N/A)

Novavax NasdaqGS:NVAX Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Location: 700 Quince Orchard Road, Gaithersburg, MD, 20878, United States | Website: https://www.novavax.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

661.7M

Cash

731.5M

Avg Qtr Burn

-47.3M

Short % of Float

34.00%

Insider Ownership

8.74%

Institutional Own.

57.18%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Update

Approved

Update

Approved

Update

Approved

Update

COVID-Influenza combination (CIC) vaccine Details
Influenza, COVID-19

Susp. Mover™

Phase 3

Data readout

Phase 3

Update

Phase 2

Update

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued

RSV Vaccine Details
Respiratory syncytial virus

Failed

Discontinued